# Arvinas Inc. (ARVN)

Source: https://www.quantisnow.com/company/ARVN
Generated: 2026-11-22T21:35:23.613Z

- Ticker: ARVN
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2018
- SEC CIK: 0001655759
- Website: arvinas.com

## About

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Bayer AG, and Insilico Medicine, Inc. Arvinas, Inc. was incorporated in 2013 and is based in New Haven, Connecticut.

## Latest ARVN news and filings

- 2026-11-18 13:00 UTC [Leadership Update] [GeneDx Announces Leadership Transition](https://www.quantisnow.com/insight/genedx-announces-leadership-transition-6798090)
- 2026-11-16 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Arvinas Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-arvinas-inc-6791973)
- 2026-11-11 12:00 UTC [Conference Announcement] [Arvinas to Present at Jefferies Global Healthcare Conference](https://www.quantisnow.com/insight/arvinas-to-present-at-jefferies-global-healthcare-conference-6785120)
- 2026-11-09 23:04 UTC [SEC Form 4] [VP, Chief Accounting Officer Loomis David K sold $1,475 worth of shares (232 units at $6.36), decreasing direct ownership by 0.58% to 39,961 units (SEC Form 4) (withholding tax)](https://www.quantisnow.com/insight/vp-chief-accounting-officer-loomis-david-k-sold-1475-worth-6782175)
- 2026-11-04 21:01 UTC [Arvinas to Present Preliminary Clinical Data from Early Monotherapy Dose Escalation Cohorts in the Phase 1 Trial for ARV-393 (Zaloblideg), a PROTAC BCL6 Degrader, at the 2026 American Society of Hematology (ASH®) Annual Meeting](https://www.quantisnow.com/insight/arvinas-to-present-preliminary-clinical-data-from-early-monotherapy-dose-6772132)
- 2026-11-03 21:37 UTC [SEC Form S-3] [SEC Form S-3 filed by Arvinas Inc.](https://www.quantisnow.com/insight/sec-form-s-3-filed-by-arvinas-inc-6770186)
- 2026-11-03 21:04 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Arvinas Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-arvinas-inc-6769509)
- 2026-11-03 13:09 UTC [SEC Form 8-K] [Arvinas Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/arvinas-inc-filed-sec-form-8-k-results-of-operations-and-6768571)
- 2026-11-03 12:00 UTC [Earnings] [Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update](https://www.quantisnow.com/insight/arvinas-reports-third-quarter-2026-financial-results-and-provides-corporate-6768356)
- 2026-10-27 20:01 UTC [Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation](https://www.quantisnow.com/insight/arvinas-announces-return-of-early-career-researcher-award-to-recognize-6759092)
- 2026-10-27 11:00 UTC [Earnings Date] [Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026](https://www.quantisnow.com/insight/arvinas-to-report-third-quarter-2026-financial-results-on-november-6758393)
- 2026-10-07 11:00 UTC [Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease](https://www.quantisnow.com/insight/arvinas-shares-novel-oculomotor-and-biomarker-data-from-phase-1-6739651)
- 2026-10-01 20:01 UTC [Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®](https://www.quantisnow.com/insight/arvinas-to-present-novel-biomarker-data-from-the-phase-1-6732283)
- 2026-09-29 20:01 UTC [Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-6729134)
- 2026-09-28 20:03 UTC [SEC Form S-8] [SEC Form S-8 filed by Arvinas Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-arvinas-inc-6727640)
- 2026-09-28 11:00 UTC [Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate](https://www.quantisnow.com/insight/arvinas-announces-first-patient-dosed-in-phase-12-clinical-trial-6727038)
- 2026-09-22 20:36 UTC [SEC Form 144] [SEC Form 144 filed by Arvinas Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-arvinas-inc-6723146)
- 2026-09-09 20:16 UTC [SEC Form 144] [SEC Form 144 filed by Arvinas Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-arvinas-inc-6710087)
- 2026-09-03 20:01 UTC [Conference Announcement] [Arvinas to Participate in Upcoming Investor Conferences](https://www.quantisnow.com/insight/arvinas-to-participate-in-upcoming-investor-conferences-6704994)
- 2026-09-01 20:01 UTC [Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-6701261)
- 2026-08-31 20:04 UTC [SEC Form S-8] [SEC Form S-8 filed by Arvinas Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-arvinas-inc-6699752)
- 2026-08-14 20:16 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Arvinas Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-arvinas-inc-6683013)
- 2026-08-04 20:13 UTC [SEC Form 144] [SEC Form 144 filed by Arvinas Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-arvinas-inc-6662273)
- 2026-08-04 20:08 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Arvinas Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-arvinas-inc-6662187)
- 2026-08-04 17:12 UTC [Analyst Downgrade] [Arvinas downgraded by Wells Fargo](https://www.quantisnow.com/insight/arvinas-downgraded-by-wells-fargo-6661663)
- 2026-08-04 11:02 UTC [SEC Form 8-K] [Arvinas Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/arvinas-inc-filed-sec-form-8-k-results-of-operations-and-6660966)
- 2026-08-04 11:00 UTC [Earnings Date] [Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://www.quantisnow.com/insight/arvinas-reports-second-quarter-2026-financial-results-and-provides-corporate-6660891)
- 2026-07-28 11:00 UTC [Earnings Date] [Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026](https://www.quantisnow.com/insight/arvinas-to-report-second-quarter-2026-financial-results-on-august-6650525)
- 2026-07-09 20:12 UTC [SEC Form 144] [SEC Form 144 filed by Arvinas Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-arvinas-inc-6633042)
- 2026-06-26 20:23 UTC [SEC Form 4] [Director Smaldone Alsup Laurie was granted 15,527 shares, increasing direct ownership by 60% to 41,572 units (SEC Form 4)](https://www.quantisnow.com/insight/director-smaldone-alsup-laurie-was-granted-15527-shares-increasing-direct-6617462)
- 2026-06-26 20:23 UTC [SEC Form 4] [Director Norwalk Leslie V was granted 15,527 shares, increasing direct ownership by 60% to 41,572 units (SEC Form 4)](https://www.quantisnow.com/insight/director-norwalk-leslie-v-was-granted-15527-shares-increasing-direct-6617455)
- 2026-06-26 20:22 UTC [SEC Form 4] [Director Morrison Briggs was granted 15,527 shares, increasing direct ownership by 16% to 111,548 units (SEC Form 4)](https://www.quantisnow.com/insight/director-morrison-briggs-was-granted-15527-shares-increasing-direct-ownership-6617454)
- 2026-06-26 20:22 UTC [SEC Form 4] [Director Kennedy Edward Moore Jr. was granted 15,527 shares, increasing direct ownership by 39% to 54,957 units (SEC Form 4)](https://www.quantisnow.com/insight/director-kennedy-edward-moore-jr-was-granted-15527-shares-increasing-6617449)
- 2026-06-26 20:21 UTC [SEC Form 4] [Director Cunningham Everett was granted 15,527 shares, increasing direct ownership by 60% to 41,572 units (SEC Form 4)](https://www.quantisnow.com/insight/director-cunningham-everett-was-granted-15527-shares-increasing-direct-ownership-6617444)
- 2026-06-26 20:21 UTC [SEC Form 4] [Director Bain Linda was granted 15,527 shares, increasing direct ownership by 60% to 41,572 units (SEC Form 4)](https://www.quantisnow.com/insight/director-bain-linda-was-granted-15527-shares-increasing-direct-ownership-6617440)
- 2026-06-25 20:18 UTC [SEC Form 8-K] [Arvinas Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/arvinas-inc-filed-sec-form-8-k-submission-of-matters-to-6615921)
- 2026-06-24 21:20 UTC [SEC Form 4] [Chief Financial Officer Saik Andrew sold $46,474 worth of shares (5,696 units at $8.16), decreasing direct ownership by 3% to 187,432 units (SEC Form 4) (for withholding tax)](https://www.quantisnow.com/insight/chief-financial-officer-saik-andrew-sold-46474-worth-of-shares-6614597)
- 2026-06-23 22:09 UTC [SEC Form 144] [SEC Form 144 filed by Arvinas Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-arvinas-inc-6613167)
- 2026-06-22 20:10 UTC [SEC Form 8-K] [Arvinas Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/arvinas-inc-filed-sec-form-8-k-leadership-update-6610719)
- 2026-06-18 20:06 UTC [SEC Form 4] [Chief Scientific Officer Cacace Angela M sold $19,565 worth of shares (2,576 units at $7.60), decreasing direct ownership by 1% to 180,390 units (SEC Form 4) to satisfy withholding obligation](https://www.quantisnow.com/insight/chief-scientific-officer-cacace-angela-m-sold-19565-worth-of-6608595)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ARVN
- Earnings history: https://www.quantisnow.com/earnings/ARVN
- Dividend history: https://www.quantisnow.com/dividends/ARVN
- Insider transactions: https://www.quantisnow.com/insiders/ARVN
- Options chain: https://www.quantisnow.com/options/ARVN
- SEC 8-K filings only: https://www.quantisnow.com/company/ARVN/8-k
- RSS and alerts for ARVN: https://www.quantisnow.com/docs/rss-feeds.md
